文献速递新发突发、热带与寄生虫病

美国重症疟疾患者接受青蒿琥酯静脉治疗后的迟发性溶血(2019年4月至2021年7月)

Post-artesunate Delayed Hemolysis in Patients With Severe Malaria in the United States-April 2019 Through July 2021.
PubMed 文献 · Clin Infect Dis · 2023-01-01

本研究纳入2019年4月至2021年7月美国332例接受静脉青蒿琥酯治疗的重症疟疾患者,其中9例(2.7%)发生青蒿琥酯后迟发性溶血(PADH)。PADH患者入院时及完成静脉青蒿琥酯后8小时内总胆红素均较高,累计剂量>9.5 mg/kg及>3次给药为危险因素,多数病例在启动治疗后2周内诊断,5例(56%)需输血,全部恢复无后遗症。

要点

  • 静脉青蒿琥酯治疗后迟发性溶血发生率为2.7%(9/332)。
  • 累计剂量>9.5 mg/kg及>3次给药为迟发性溶血危险因素。
  • 多数病例在启动青蒿琥酯后2周内诊断,5例需输血,均恢复无后遗症。

核心结论

  • 青蒿琥酯后迟发性溶血在许多病例中是不常见且自限性的不良事件;每周监测血红蛋白和溶血标志物可能及时识别需要干预的病例。

研究设计与样本

  • 研究纳入2019年4月至2021年7月美国诊断为重症疟疾并接受静脉青蒿琥酯治疗的患者,共332例,采用比例、中位数和四分位距描述人口学、临床、实验室、治疗和结局指标。
  • 将报告发生青蒿琥酯后迟发性溶血的患者与未报告该事件的患者进行比较,并进行显著性检验。

主要发现

  • 332例患者中9例(2.7%)发生青蒿琥酯后迟发性溶血。
  • 两组多数感染者为非西班牙裔黑人;疟原虫密度(11.0% vs 8.0%)和入院血红蛋白(11.0 g/dL vs 11.8 g/dL)相似。
  • 青蒿琥酯后迟发性溶血患者入院时总胆红素(4.7 mg/dL vs 2.2 mg/dL)及完成静脉青蒿琥酯后8小时内总胆红素(2.6 mg/dL vs 1.2 mg/dL)均高于无迟发性溶血组。
  • 累计静脉青蒿琥酯剂量>9.5 mg/kg和>3次给药为青蒿琥酯后迟发性溶血的危险因素。
  • 9例青蒿琥酯后迟发性溶血中7例在启动静脉青蒿琥酯后2周内诊断;5例(56%)需要输血,全部恢复无后遗症。

临床怎么用

  • 作者认为,每周监测血红蛋白和溶血标志物可能及时识别需要干预的病例。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Studies have demonstrated the safety and efficacy of intravenous artesunate (IVAS) for treatment of severe malaria in endemic and nonendemic countries. However, post-artesunate delayed hemolysis (PADH) is an increasingly recognized phenomenon after its administration. This study describes the prevalence and outcomes of PADH events among severe malaria cases treated with IVAS in the United States. METHODS: Patients diagnosed with severe malaria and treated with IVAS from April 2019 to July 2021 were included. Demographic, clinical, laboratory, therapeutic, and outcome measures were described using proportions, medians, and interquartile range. Patients reported to experience PADH were compared with those not reported to have PADH, and tests of significance were performed. RESULTS: Of 332 patients included in our analysis, 9 (2.7%) experienced PADH. The majority of infections in both groups were in non-Hispanic Black individuals. Parasite density (11.0% vs 8.0%), admission hemoglobin (11.0 g/dL vs 11.8 g/dL) were similar in the 2 groups. Total bilirubin levels at admission (4.7 mg/dL vs 2.2 mg/dL) and within 8 hours after completion of IVAS (2.6 mg/dL vs 1.2 mg/dL) were notably higher in PADH patients. Cumulative IVAS dose of >9.5 mg/kg and >3 doses of IVAS were risk factors for PADH. The majority (7 of 9) of PADH cases were diagnosed within 2 weeks after initiation of IVAS. Five patients (56%) required blood transfusions, and all recovered without sequelae. CONCLUSIONS: PADH is an uncommon and self-limiting adverse event in many cases; weekly monitoring of hemoglobin and hemolytic markers may identify cases requiring intervention in a timely manner.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Abanyie F, Ng J, Tan KR, et al. Post-artesunate Delayed Hemolysis in Patients With Severe Malaria in the United States-April 2019 Through July 2021. Clin Infect Dis. 2023. PMID: 36052468. doi:10.1093/cid/ciac719

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。